RXRX icon

Recursion Pharmaceuticals
RXRX

Overview Fund Activity

198 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 70 increasing their positions, 48 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
198
Holders Change
+6
Holders Change %
+3.13%
% of All Funds
2.9%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
42
Increased
70
Reduced
48
Closed
34
Calls
$8.93M
Puts
$4.35M
Net Calls
+$4.58M
Net Calls Change
+$4.79M

Top Buyers

1
AIM
1
ARK Investment Management
Florida
$204M
2
Sumitomo Mitsui Trust Group
2
Sumitomo Mitsui Trust Group
Japan
$90.7M
3
NAMA
3
Nikko Asset Management Americas
New York
$90.6M
4
Morgan Stanley
4
Morgan Stanley
New York
$50.8M
5
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$14.5M

Top Sellers

1
AI
1
ArchPoint Investors
Florida
$0
2
JPMorgan Chase & Co
2
JPMorgan Chase & Co
New York
$3.75M
3
Millennium Management
3
Millennium Management
New York
$0
4
Nuveen Asset Management
4
Nuveen Asset Management
Illinois
$5.49M
5
Baillie Gifford & Co
5
Baillie Gifford & Co
United Kingdom
$238M
Name Holding Trade Value Shares
Change 		Shares
Change %
Allspring Global Investments
226
Allspring Global Investments
North Carolina
– -$77.4K -10,123 Closed
Belvedere Trading
227
Belvedere Trading
Illinois
– -$48.5K -6,340 Closed
Group One Trading
228
Group One Trading
Illinois
– -$47.7K -6,229 Closed
Toronto Dominion Bank
229
Toronto Dominion Bank
Ontario, Canada
– -$566 -74 Closed
6 7 8 9
10